The FDA you designed your protocol around may no longer exist. In this episode, Darshan Kulkarni breaks down why clinical researchers, regulatory attorneys, and promotional review teams need to pay attention—now.

With mass layoffs, frozen guidances, and a reorganization shaking CDER and CBER to their core, trial timelines, IRB reliance, and even legal interpretations are in flux. Marketing teams are flying blind with the FDA’s communications division gutted and post-Loper Bright challenges looming large.

Darshan outlines urgent next steps:
✔️ Rethink your submission timelines
✔️ Reassess your SOPs for oversight and reporting
✔️ Update your promotional risk strategy—especially in digital

If you're in life sciences and relying on yesterday’s FDA to approve tomorrow’s innovation, it’s time to rethink.

Reach out to the Kulkarni Law Firm—we specialize in compliance during regulatory chaos.

Support the show